cutaneous medicine part 3
DESCRIPTION
CUTANEOUS MEDICINE PART 3. TOM PAIGE DEPARTMENT OF DERMATOLOGY CCRMC. Diabetes mellitus Thyroid disease Cushing’s syndrome Acromegaly Gastrointestinal disease Renal disease. Medical Disorders. Best Answer(s). (A). Three slides represent examples of palpable purpura - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/1.jpg)
CUTANEOUS MEDICINE PART 3
TOM PAIGEDEPARTMENT OF DERMATOLOGYCCRMC
![Page 2: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/2.jpg)
Medical Disorders
Diabetes mellitusThyroid diseaseCushing’s syndromeAcromegalyGastrointestinal diseaseRenal disease
![Page 3: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/3.jpg)
![Page 4: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/4.jpg)
Best Answer(s)
(A). Three slides represent examples of palpable purpura(B). Platelet count is less than 10,000/mm3
(C). Platelet count is greater than 1,000,000/mm3
(D). Petechiae are usually 5 mm or larger in size and non-palpable.(E). B. and C. are the correct answers
![Page 5: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/5.jpg)
Petechiae
![Page 6: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/6.jpg)
![Page 7: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/7.jpg)
![Page 8: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/8.jpg)
![Page 9: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/9.jpg)
QuickTime™ and a decompressor
are needed to see this picture.
![Page 10: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/10.jpg)
![Page 11: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/11.jpg)
![Page 12: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/12.jpg)
Hematologic diseases
Cutaneous hemorrhages Petechiae Ecchymoses
Generalized pruritisLeukemia may be associated w/ Sweet’s syndrome or pyoderma gangrenosumLeukemia/lymphoma sometimes causes red, purpuric or ulcerated skin nodules
![Page 13: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/13.jpg)
![Page 14: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/14.jpg)
![Page 15: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/15.jpg)
![Page 16: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/16.jpg)
![Page 17: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/17.jpg)
![Page 18: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/18.jpg)
QuickTime™ and a decompressor
are needed to see this picture.
![Page 19: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/19.jpg)
![Page 20: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/20.jpg)
![Page 21: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/21.jpg)
Best Answer(s)
A. These slides represent cutaneous lymphomasB. Cutaneous lymphomas are the second most common group of extra nodal lymphomasC. B-cell lymphomas occur in the skinD. Mycosis fungoides is the most common form of cutaneous lymphomaE. (A) and (D)F. All the above
![Page 22: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/22.jpg)
![Page 23: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/23.jpg)
![Page 24: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/24.jpg)
QuickTime™ and a decompressor
are needed to see this picture.
![Page 25: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/25.jpg)
![Page 26: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/26.jpg)
Best Answer(s)
A. Mycosis fungoides is a CD4 helper T-cell malignancyB. CD8 suppressor T-cells are the predominate cell type in mycosis fungoidesC. Both A. and B.D. Neither A. and B.
![Page 27: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/27.jpg)
![Page 28: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/28.jpg)
![Page 29: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/29.jpg)
![Page 30: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/30.jpg)
![Page 31: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/31.jpg)
![Page 32: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/32.jpg)
![Page 33: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/33.jpg)
![Page 34: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/34.jpg)
![Page 35: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/35.jpg)
![Page 36: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/36.jpg)
![Page 37: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/37.jpg)
![Page 38: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/38.jpg)
![Page 39: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/39.jpg)
![Page 40: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/40.jpg)
![Page 41: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/41.jpg)
![Page 42: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/42.jpg)
![Page 43: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/43.jpg)
![Page 44: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/44.jpg)
![Page 45: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/45.jpg)
![Page 46: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/46.jpg)
![Page 47: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/47.jpg)
![Page 48: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/48.jpg)
![Page 49: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/49.jpg)
![Page 50: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/50.jpg)
Best Answers
A. All of the porphyrias have a photo component.B. Diagnosis may be made by examination of urine, feces, and blood. C. There is a strong association between hepatitis C virus and PCT D. (B.) and (C.)E. None of the above
![Page 51: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/51.jpg)
Porphyria
Porphyrias are due to abnormalities of the heme pathway and result in cutaneous photosensitivity.Diagnosis is confirmed by detection of excessive porphyrins in Blood Urine Feces
![Page 52: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/52.jpg)
![Page 53: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/53.jpg)
The most common porphyrias seen by dermatologists are Erythropoietic protoporphyria (EPP) Porphyria cutanea tarda (PCT) Variegate porphyria (VP)
![Page 54: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/54.jpg)
EPP
![Page 55: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/55.jpg)
![Page 56: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/56.jpg)
EPP SYMPTOMS
EDEMA SUN -INDUCED ERYTHEMAACUTE PAINFUL PHTODERMATITISURTICARIA
![Page 57: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/57.jpg)
Porphyria Cutanea Tarda
![Page 58: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/58.jpg)
QuickTime™ and a decompressor
are needed to see this picture.
![Page 59: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/59.jpg)
QuickTime™ and a decompressor
are needed to see this picture.
![Page 60: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/60.jpg)
PCT
![Page 61: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/61.jpg)
![Page 62: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/62.jpg)
![Page 63: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/63.jpg)
![Page 64: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/64.jpg)
![Page 65: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/65.jpg)
![Page 66: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/66.jpg)
![Page 67: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/67.jpg)
![Page 68: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/68.jpg)
![Page 69: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/69.jpg)
![Page 70: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/70.jpg)
![Page 71: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/71.jpg)
![Page 72: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/72.jpg)
VP
![Page 73: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/73.jpg)
![Page 74: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/74.jpg)
PCT AND VP SYMPTOMS
BLISTERING LESIONSKIN FRAGILITYSCARRINGHYPERPIGMENTATIONPOSSIBLE HYPERTRICHOSIS
![Page 75: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/75.jpg)
![Page 76: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/76.jpg)
![Page 77: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/77.jpg)
Hyperlipidemias
The disorders of lipid metabolism with cutaneous manifestations are primarily the hyperlipoproteinemias (hyperlipidemias).They can be Primary Secondary
![Page 78: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/78.jpg)
Primary Hyperlipoproteinemias
Elevated lipoprotein class Chylomicrons Chylomicrons and VLDLs VLDLs LDLs LDLs and VLDLs IDLs
![Page 79: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/79.jpg)
Table 22–1 -- Primary hyperlipoproteinemias
Elevated lipoprotein class
Synonyms and primary disorders
Chylomicrons
Type I, familial lipoprotein lipase deficiency, familial apoprotein C-II deficiencies
Chylomicrons and VLDLs
Type V, familial combined hyperlipidemia
VLDLs
Type IV, endogenous familial hypertriglyceridemiaL
DLs
Type IIa, familial hypercholesterolemia, familial combined hyperlipidemia
LDLs and VLDLs
Type IIb, familial multiple lipoprotein-type hyperlipidemia, combined hyperlipidemiaI
DLs
Type III, remnant hyperlipidemia, familial dysbetalipoproteinemia
VLDL = very-low-density lipoprotein, LDL = low-density lipoprotein, IDL = intermediate-density lipoprotein
Primary Hyperlipoproteinemias
![Page 80: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/80.jpg)
Secondary Hyperlipoproteinemias
Secondary hypercholesterolemiaSecondary hypertriglyceridemia
![Page 81: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/81.jpg)
Secondary hypercholesterolemia
Acute intermittent porphyria Cholestasis Hypothyroidism Pregnancy
![Page 82: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/82.jpg)
Secondary Hypertriglyceridemia
MetabolicRenalHepaticHormonalLife styleMedications
![Page 83: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/83.jpg)
Clinical Presentation of Hyperlipidemias
XanthelasmaEruptive, tuberous, plane, or tendinous xanthoma
![Page 84: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/84.jpg)
![Page 85: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/85.jpg)
![Page 86: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/86.jpg)
![Page 87: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/87.jpg)
![Page 88: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/88.jpg)
![Page 89: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/89.jpg)
![Page 90: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/90.jpg)
![Page 91: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/91.jpg)
![Page 92: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/92.jpg)
![Page 93: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/93.jpg)
![Page 94: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/94.jpg)
![Page 95: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/95.jpg)
![Page 96: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/96.jpg)
![Page 97: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/97.jpg)
![Page 98: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/98.jpg)
![Page 99: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/99.jpg)
![Page 100: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/100.jpg)
![Page 101: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/101.jpg)
![Page 102: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/102.jpg)
![Page 103: CUTANEOUS MEDICINE PART 3](https://reader036.vdocument.in/reader036/viewer/2022081512/56814cbe550346895db9cb93/html5/thumbnails/103.jpg)
QuickTime™ and a decompressor
are needed to see this picture.